Eli Lilly and Company
MET antibody drug conjugates
Last updated:
Abstract:
Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.
Status:
Grant
Type:
Utility
Filling date:
17 Nov 2017
Issue date:
9 Nov 2021